Biogen launches defence of contentious $56,000 Alzheimer’s drug

biogen launches defence of contentious 56000 alzheimers drug

Sumary of Biogen launches defence of contentious $56,000 Alzheimer’s drug:

  • Biogen has issued a staunch defence of the science and approval process behind its controversial Alzheimer’s drug, saying that “misinformation” is fuelling criticism of the treatment.
  • ” The treatment, which is sold under the brand name Aduhelm, “was approved appropriately on very solid grounds and represented the right thing to do”, he said.
  • Some scientists have said the treatment does not work and should never have been given the go-ahead, while others allege that the US medicines regulator and the drugmaker had collaborated too closely in the run-up to the approval.
  • The $56,000-a-year infusion treatment is the first Alzheimer’s drug to be given the green light in nearly two decades.
  • Michael McDonnell, Biogen’s chief financial officer, said the Massachusetts-based drugmaker welcomed the formal review and that it would be “good for everyone involved to ensure confidence in the therapy”.
  • Biogen said revenues from Aduhelm hit $2 million in the second quarter, but Vounatsos noted that a “big chunk” of the sales were inventory and did not reveal the number of patients who have started treatment.
  • Amyloid-clearing drugsAduhelm is designed around the amyloid hypothesis, whose proponents say that clumps of protein building up in the brain cause Alzheimer’s.
  • Numerous pharmaceutical companies have previously tried and failed to develop amyloid-clearing drugs and prove that removing the proteins can mitigate the disease.

Want to know more click here go to source.

From -

Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.